Jennifer E. Pogoriler

The paper constructs a single-cell atlas of PVOD across the lifespan, identifying endothelial dysfunction and molecular pathways as key drivers of the disease with potential therapeutic targets.

This paper identifies DLK1 as a novel immunotherapeutic target in adrenocortical carcinoma, showing it regulates tumor cell plasticity and chemoresistance, and demonstrates the efficacy of a DLK1-targeting antibody-drug conjugate.

This study identifies DLK1 as a potential immunotherapeutic target in neuroblastoma through integrative proteomic, transcriptomic, and epigenomic analysis.